This top fund manager just called these leading ASX shares a buy

WAM thinks that these two ASX shares are buys.

| More on:
A stopwatch ticking close to the 12 where the words on the face say 'Time to Buy' indicating its the bottom of the falling market and time to buy ASX shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Fund manager Wilson Asset Management (WAM) has outlined two ASX shares with potential
  • The first stock is pathology business Australian Clinical Labs which is benefiting from the high level of COVID testing
  • The second company is building and restoration services Johns Lyng which is growing market share and opening up new growth opportunities

Leading fund manager Wilson Asset Management (WAM) has named two ASX shares in its portfolios that it thinks are buys.

Every month, WAM talks about some of the businesses that have performed well and outlines the bullish factors for thinking about the stocks.

Two of the featured ASX shares this month comes from WAM Research Limited (ASX: WAX) and WAM Capital Limited (ASX: WAM), which sometimes target opportunities from the smaller end of the ASX, like these two:

Australian Clinical Labs Ltd (ASX: ACL)

Australian Clinical Labs is described as a leading provider of pathology services in Australia, with 86 accredited laboratories performing services for more than 8 million people annually.

In December, Australian Clinical Labs upgraded its expectations for the FY22 first-half net profit after tax (NPAT) to between $116.3 million to $128 million. This was increased from the previous guidance of between $86.3 million to $94.9 million.

The fund manager notes that the ASX share is experiencing strong demand for coronavirus testing, particularly during the Omicron variant outbreak and recently completed the acquisition of Medlab Pathology, doubling its market share to 20.4% in New South Wales.

WAM thinks that Australian Clinical Labs is a high-quality pathology business that can continue to grow organically through market share gains, due to its "superior technology and processes". The fund manager notes that Australian Clinical Labs has a very strong balance sheet and it also sees the potential for acquisitions in the future that can add to profit.

Johns Lyng Group Ltd (ASX: JLG)

Another ASX share that WAM likes is Johns Lyng which provides building and restoration services across Australia for properties and contents damaged by insurable events, including impact, weather, and fire events.

It operates in all major metropolitan areas and in high-risk regional areas, such as Far North Queensland.

WAM pointed out that in December, the company announced the acceleration of its US growth strategy through the acquisition of Reconstruction Experts, a leading provider of insurance-focused vendor managed repairs services for US$144 million.

This acquisition, considered highly strategic, adds to the company's earnings per share (EPS) and equated to 7.8x earnings before interest, tax, depreciation and amortisation (EBITDA) for the 12 months to 30 June 2021.

The fund manager decided to invest in Johns Lyng Group based on the view that as the largest and most sophisticated provider of emergency building works, the company will continue to grow through market share gains and acquisition.

WAM believes that with the recent acquisition, the company has added another material growth pillar that will underpin longer-term aspirations and earnings growth.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Clinical Labs Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Opinions

Smiling teenager boy and laughing girls show off their balancing skills by walking in a row on a wall in the autumnal sunny city park.
ETFs

Two ASX ETFs to balance your portfolio as a new investor in 2025

If I restarted my portfolio from scratch, these ETFs would be my first two holdings.

Read more »

A guy wearing glasses tries to show off his muscles.
Opinions

Could these Australian shares help investors beat the ASX 200?

There are quite a few reasons why I'm bullish about these stocks.

Read more »

Two men laughing while bouncing on bouncy balls
Energy Shares

The two ASX energy stocks I think are set to rebound in 2025

After a shocking 2024, could these two energy companies power up again this year?

Read more »

Opinions

Why I think these 2 bargain ASX 300 shares are buys

2025 could be a good year for these stocks, here’s why…

Read more »

Happy construction worker at a building site with a group of workers at the background.
Opinions

Why these 2 ASX 300 shares were my latest investments

I’m excited about the potential of these stocks.

Read more »

Happy young couple saving money in piggy bank.
Opinions

Want to start investing in ASX shares? Here's what I'd buy

This is where I’d begin to put my money in the stock market.

Read more »

People of different ethnicities in a room taking a big selfie, symbolising diversification.
Opinions

Want diversification? Get it instantly with these ASX 200 shares

Some businesses offer a lot more diversification than others.

Read more »

A happy man and woman on a computer at Christmas, indicating a positive trend for retail shares.
Opinions

2 ASX 200 shares I'd want to receive as a present today

Merry Christmas! Are there any stocks under your tree?

Read more »